PROCEPT BioRobotics Corp
For the period ended Dec 31, 2024. Filed Feb 27, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Feb 27, 2025
PRCT$23.05+3.0%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Cash Flows F-
(in thousands)
| Year Ended December 31, | |||
|---|---|---|---|
| 2024 | 2023 | 2022 | |
| Cash flows from operating activities: | |||
| Net loss | $(91,413) | $(105,897) | $(87,154) |
| Adjustments to reconcile net loss to cash used in operating activities: | |||
| Depreciation and amortization | 5,234 | 3,807 | 2,841 |
| Stock-based compensation expense | 31,840 | 19,134 | 10,337 |
| Change in fair value in derivative liability | 114 | 107 | 283 |
| Non-cash lease adjustment | (383) | 13 | 1,478 |
| Provision for credit losses | 840 | — | — |
| Inventory write-down | 1,881 | 995 | 62 |
| Loss on loan extinguishment | — | — | 3,258 |
| Changes in operating assets and liabilities: | |||
| Accounts receivable, net | (35,960) | (33,103) | (10,809) |
| Inventory | (17,235) | (9,751) | (15,251) |
| Prepaid expenses and other current assets | (3,211) | 1,051 | (1,880) |
| Other assets | (1,637) | (868) | (51) |
| Accounts payable | (2,152) | 5,789 | 3,959 |
| Accrued compensation | 4,652 | 3,438 | 6,972 |
| Accrued interest expense | 134 | 125 | 757 |
| Deferred revenue | 3,716 | 3,317 | 1,830 |
| Operating lease liabilities | 2,596 | 4,989 | 327 |
| Other liabilities | 1,771 | (1,149) | 2,659 |
| Net cash used in operating activities | (99,213) | (108,003) | (80,382) |
| Cash flows from investing activities: | |||
| Purchases of property and equipment | (4,409) | (25,206) | (2,653) |
| Net cash used in investing activities | (4,409) | (25,206) | (2,653) |
| Cash flows from financing activities: | |||
| Proceeds from issuance of common stock under employee stock purchase plan | 4,527 | 3,610 | 2,409 |
| Proceeds from issuance of common stock from the exercise of stock options, net | 11,075 | 2,480 | 4,008 |
| Proceeds from issuance of common stock, net of issuance costs | 164,523 | 161,705 | — |
| Proceeds from issuance of long-term debt, net of issuance costs | — | — | 51,195 |
| Payment of principal on long-term debt | — | — | (50,000) |
| Payment of final payment fee | — | — | (3,000) |
| Payment of prepayment fee | — | — | (1,000) |
| Net cash provided by financing activities | 180,125 | 167,795 | 3,612 |
| Net increase (decrease) in cash, cash equivalents and restricted cash | 76,503 | 34,586 | (79,423) |
| Cash, cash equivalents and restricted cash | |||
| Beginning of the period | 260,260 | 225,674 | 305,097 |
| End of the period | $336,763 | $260,260 | $225,674 |
| Reconciliation of cash, cash equivalents and restricted cash to balance sheets: | |||
| Cash and cash equivalents | $333,725 | $257,222 | $221,859 |
| Restricted cash | 3,038 | 3,038 | 3,815 |
| Cash, cash equivalents and restricted cash in balance sheets | $336,763 | $260,260 | $225,674 |
| Supplemental cash flow information | |||
| Interest paid | $3,970 | $4,056 | $4,291 |
| Non-cash investing and financing activities | |||
| Transfer of evaluation units from inventory to property and equipment, net | $106 | $347 | $124 |
| Property and equipment included in accounts payable and accrued expenses | $348 | $1,863 | $3,544 |
| Right-of-use assets obtained in exchange for operating lease liabilities | $— | $— | $22,854 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.